Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.

PubWeight™: 0.75^‹?›

🔗 View Article (PMC 4355660)

Published in Contemp Oncol (Pozn) on December 31, 2014

Authors

Marek Wojtukiewicz¹, Ewa Chmielowska², Emilia Filipczyk-Cisarż³, Krzysztof Krzemieniecki⁴, Krzysztof Leśniewski-Kmak⁵, Maria M Litwiniuk⁶, Karolina Wieruszewska-Kowalczyk⁷, Elżbieta Kosno-Kruszewska⁷

Author Affiliations

1: Department of Oncology, Medical University, Comprehensive Cancer Center, Bialystok, Poland.
2: Oncology Clinic, Oncology Centre, Bydgoszcz, Poland.
3: Chemotherapy Department, Lower Silesian Oncology Centre, Wroclaw, Poland.
4: Oncology Department, Jagiellonian University, Krakow, Poland.
5: Department of Oncology and Radiotherapy, Gdynia Oncology Centre, and Department of Propedeutical Oncology, Medical University of Gdansk, Gdynia, Poland.
6: Clinic of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
7: Amgen Biotechnologia Sp. z o.o., Warsaw, Poland.

Articles cited by this ↗

American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol (2007) 2.05

Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw (2005) 1.73

Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw (2009) 1.63

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol (2010) 1.51

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer (2010) 1.34

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat (2008) 1.25

Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer (2010) 1.15

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer (2007) 1.14

A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ (2013) 1.13

Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med (2013) 1.13

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract (2013) 0.93

Articles by these authors ⇆

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn) (2013) 0.87

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland. Contemp Oncol (Pozn) (2014) 0.75